Table 1.

Patient characteristics (N = 1,012)

VariableNumber (%)PIK3CA mutation (%)Wild-type PIK3CA (%)P
All1,012 (100)105 (100)907 (100)NA
Gender
 Men462 (46)37 (35)425 (47)0.029a
 Women550 (54)68 (65)482 (53)
Median age58; range, 13–9156; range, 16–8159; range,13–910.26b
Ethnicity
 White796 (79)81 (77)715 (79)0.24c
 African-American96 (9)13 (12)83 (9)
 Hispanic74 (7)4 (4)70 (8)
 Asian46 (5)7 (7)39 (4)
Site of biopsy
 Primary tumor514 (51)59 (56)455 (50)0.26d
 Metastatic tumor498 (49)46 (44)452 (50)
Tumor type
 Colorectal195 (19)32 (30)163 (18)NA
 Ovarian112 (11)11 (10)101 (11)
 Melanoma88 (9)2 (2)86 (9)
 Non–small cell lung58 (6)5 (5)53 (6)
 Breast54 (5)15 (14)39 (4)
 Head and neck: squamous53 (5)8 (8)45 (5)
 Endometrial46 (5)12 (11)34 (4)
 Thyroid40 (4)2 (2)38 (4)
 Soft tissue sarcomas37 (4)0 (0)37 (4)
 Renal cell29 (3)2 (2)27 (3)
 Pancreatic26 (3)1 (1)25 (3)
 Gastric25 (2)1 (1)24 (3)
 Prostate24 (2)0 (0)24 (3)
 Neuroendocrine24 (2)1 (1)23 (3)
 Cervical: squamous20 (2)6 (6)14 (2)
 Biliary tract20 (2)0 (0)20 (2)
 Salivary gland17 (2)0 (0)17 (2)
 Head and neck: nonsquamous15 (1)2 (2)13 (1)
 Hepatocellular12 (1)0 (0)12 (1)
 Cervical: adenocarcinoma10 (1)0 (0)10 (1)
 Ewing sarcoma10 (1)0 (0)10 (1)
 Other97 (10)5 (5)92 (10)
KRAS mutations — total tested717 (100)86 (100)631 (100)
KRAS mutatede,f137 (19)31 (36)106 (17)<0.001e
KRAS wild-typee,f580 (81)55 (64)525 (83)

Abbreviation: NA, not applicable.

fTested for KRAS, n = 717 (PIK3CA mutation, n = 86; wild-type PIK3CA, n = 631).

  • aPIK3CA mutations were more prevalent in women than in men.

  • bNo difference in prevalence of PIK3CA mutations and age.

  • cNo difference in prevalence of PIK3CA mutations among different ethnic groups.

  • dNo difference in prevalence of PIK3CA mutations and site of biopsy.

  • eKRAS mutations were more prevalent in patients with PIK3CA mutations.